GlassScriptPhysician profile
Olivia Margaret Hull
NPI 1841634789
$1,052.70
in general payments reported to CMS, 2019-2025
23 companies · $17.02 in 2025
The $17.02 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.02 · 2022: $688 · 2023: $260 · 2024: $53.68 · 2025: $17.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.53 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $217.13 | 2022-2023 | |
| Amgen INC. | $137.38 | 2021-2022 | |
| Pfizer INC. | $107.89 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $55.66 | 2022-2023 | Lynparza |
| Genzyme Corporation | $49.90 | 2022-2023 | |
| Abbvie INC. | $48.25 | 2023-2024 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $47.86 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $47.83 | 2022-2023 | Trodelvy |
| Astellas Pharma US INC | $47.43 | 2022-2024 | Padcev |
| Exelixis INC. | $41.20 | 2022 | |
| Kite Pharma, INC. | $40.29 | 2022-2023 | |
| Seagen INC. | $30.50 | 2022-2023 | Adcetris |
| Servier Pharmaceuticals LLC | $22.76 | 2024 | |
| Daiichi Sankyo INC. | $22.51 | 2022 | |
| Morphosys, US INC. | $20.00 | 2023 | Monjuvi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.88 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2025 | Libtayo |
| Janssen Biotech, INC. | $15.84 | 2022 | |
| Mirati Therapeutics, INC. | $14.04 | 2023 | Krazati |
| Genentech USA, INC. | $14.03 | 2023 | Tecentriq |
| Glaxosmithkline, LLC. | $13.46 | 2022 | |
| Myovant Sciences INC. | $12.34 | 2022 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.